Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DX-106
- Development stage
- Preclinical
- Lead developer
- Delonix Bioworks
- Modality
- Vaccines & Immunotherapeutics
01
Overview
DX-106 is a preclinical vaccine candidate developed by Delonix Bioworks using its proprietary BioDVax platform. The BioDVax platform is one of three synthetic biology-based platforms utilized by the company to create next-generation bacterial vaccines, often focusing on genetically detoxified components or specific antigen-based immune stimulation. DX-106 is currently in the lead optimization stage of development and has been licensed out to an undisclosed partner. While the specific target pathogen and indication for DX-106 have not been publicly revealed, the program represents a key asset in Delonix's pipeline of innovative bacterial vaccines.
Beyond the preview
Go deeper on DX-106.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DX-106.